In fact, a study by Zingg et al. demonstrated that EZH2 overexpression silences immunogenicity and antigen presentation in cancers such as melanoma, which serves as a gold standard for studying neoantigen biology in tumors (30). The gene discussed is EZH2; the disease is cancer.